| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telemedicine | 7 | 2023 | 187 | 4.300 |
Why?
|
| Managed Care Programs | 16 | 2013 | 356 | 2.590 |
Why?
|
| Humans | 121 | 2023 | 18058 | 1.960 |
Why?
|
| Osteoporosis | 11 | 2017 | 87 | 1.750 |
Why?
|
| Physician Assistants | 4 | 2017 | 11 | 1.670 |
Why?
|
| Nurse Practitioners | 4 | 2017 | 25 | 1.650 |
Why?
|
| Patient Education as Topic | 12 | 2017 | 215 | 1.620 |
Why?
|
| Health Behavior | 9 | 2017 | 379 | 1.530 |
Why?
|
| Transgender Persons | 7 | 2020 | 45 | 1.530 |
Why?
|
| Primary Health Care | 11 | 2017 | 843 | 1.530 |
Why?
|
| Georgia | 18 | 2023 | 43 | 1.450 |
Why?
|
| Adult | 58 | 2023 | 7696 | 1.420 |
Why?
|
| Male | 78 | 2022 | 10173 | 1.320 |
Why?
|
| Female | 84 | 2022 | 12838 | 1.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2017 | 393 | 1.240 |
Why?
|
| Health Promotion | 6 | 2017 | 295 | 1.230 |
Why?
|
| Social Support | 4 | 2022 | 211 | 1.220 |
Why?
|
| Middle Aged | 64 | 2022 | 8073 | 1.210 |
Why?
|
| Referral and Consultation | 4 | 2017 | 178 | 1.180 |
Why?
|
| Pandemics | 7 | 2023 | 293 | 1.140 |
Why?
|
| United States | 45 | 2023 | 4119 | 1.100 |
Why?
|
| Retrospective Studies | 27 | 2023 | 2498 | 1.070 |
Why?
|
| Patient Satisfaction | 7 | 2023 | 233 | 1.060 |
Why?
|
| Ambulatory Care | 11 | 2023 | 274 | 1.030 |
Why?
|
| Insurance, Health | 5 | 2022 | 221 | 1.020 |
Why?
|
| Aged | 49 | 2022 | 6258 | 0.990 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2021 | 397 | 0.890 |
Why?
|
| Health Maintenance Organizations | 16 | 2014 | 481 | 0.850 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 445 | 0.840 |
Why?
|
| Patient Care Team | 5 | 2012 | 130 | 0.840 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 128 | 0.810 |
Why?
|
| Neoplasms | 11 | 2014 | 464 | 0.800 |
Why?
|
| Transsexualism | 2 | 2020 | 12 | 0.740 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 163 | 0.740 |
Why?
|
| Health Literacy | 7 | 2019 | 45 | 0.730 |
Why?
|
| Ozone | 1 | 2020 | 12 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 351 | 0.730 |
Why?
|
| Gender Identity | 5 | 2020 | 41 | 0.720 |
Why?
|
| Air Pollutants | 1 | 2020 | 48 | 0.700 |
Why?
|
| Air Pollution | 1 | 2020 | 40 | 0.690 |
Why?
|
| Electronic Health Records | 7 | 2023 | 734 | 0.690 |
Why?
|
| Hospitalization | 3 | 2021 | 813 | 0.680 |
Why?
|
| Algorithms | 3 | 2021 | 235 | 0.670 |
Why?
|
| Adolescent | 26 | 2020 | 3714 | 0.670 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 75 | 0.670 |
Why?
|
| Physician-Patient Relations | 9 | 2017 | 202 | 0.670 |
Why?
|
| Young Adult | 19 | 2020 | 2479 | 0.620 |
Why?
|
| Medical Errors | 5 | 2015 | 22 | 0.610 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2017 | 5 | 0.600 |
Why?
|
| Counseling | 3 | 2017 | 199 | 0.590 |
Why?
|
| Nurse's Role | 1 | 2017 | 8 | 0.580 |
Why?
|
| Health Status | 5 | 2022 | 331 | 0.570 |
Why?
|
| Comprehension | 5 | 2015 | 21 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 92 | 0.510 |
Why?
|
| Research Design | 4 | 2023 | 393 | 0.500 |
Why?
|
| Deductibles and Coinsurance | 2 | 2014 | 33 | 0.480 |
Why?
|
| Cost Sharing | 2 | 2023 | 40 | 0.480 |
Why?
|
| Patient Compliance | 3 | 2023 | 303 | 0.480 |
Why?
|
| European Continental Ancestry Group | 5 | 2017 | 559 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2015 | 742 | 0.470 |
Why?
|
| Hypertension | 4 | 2016 | 489 | 0.470 |
Why?
|
| Cohort Studies | 17 | 2023 | 2631 | 0.470 |
Why?
|
| Surveys and Questionnaires | 11 | 2022 | 1346 | 0.460 |
Why?
|
| Occupational Health Services | 1 | 2013 | 17 | 0.460 |
Why?
|
| Absorptiometry, Photon | 9 | 2019 | 59 | 0.450 |
Why?
|
| Chronic Disease | 7 | 2017 | 462 | 0.450 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 119 | 0.420 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 131 | 0.420 |
Why?
|
| African Americans | 3 | 2017 | 485 | 0.410 |
Why?
|
| Diabetes Mellitus | 5 | 2011 | 526 | 0.410 |
Why?
|
| Back Pain | 3 | 2023 | 36 | 0.400 |
Why?
|
| Child | 16 | 2022 | 2519 | 0.390 |
Why?
|
| Bone Density | 6 | 2019 | 98 | 0.390 |
Why?
|
| Medicare Part D | 1 | 2011 | 22 | 0.390 |
Why?
|
| Health Care Costs | 4 | 2017 | 253 | 0.390 |
Why?
|
| User-Computer Interface | 1 | 2011 | 29 | 0.380 |
Why?
|
| Databases, Factual | 9 | 2021 | 330 | 0.380 |
Why?
|
| Self Care | 4 | 2016 | 175 | 0.380 |
Why?
|
| Diagnosis-Related Groups | 4 | 2004 | 31 | 0.380 |
Why?
|
| Social Media | 1 | 2011 | 13 | 0.380 |
Why?
|
| Residence Characteristics | 1 | 2013 | 248 | 0.370 |
Why?
|
| Linear Models | 2 | 2008 | 240 | 0.370 |
Why?
|
| Patient Participation | 4 | 2019 | 143 | 0.370 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 613 | 0.360 |
Why?
|
| Hepatitis C | 1 | 2011 | 66 | 0.360 |
Why?
|
| Drug Utilization | 5 | 2006 | 134 | 0.360 |
Why?
|
| Arthritis | 4 | 2018 | 9 | 0.350 |
Why?
|
| Iatrogenic Disease | 2 | 2001 | 10 | 0.350 |
Why?
|
| Health Records, Personal | 1 | 2009 | 15 | 0.350 |
Why?
|
| Influenza, Human | 2 | 2023 | 277 | 0.350 |
Why?
|
| Outcome Assessment (Health Care) | 3 | 2007 | 248 | 0.350 |
Why?
|
| Community Participation | 1 | 2009 | 34 | 0.350 |
Why?
|
| Antihypertensive Agents | 3 | 2010 | 170 | 0.350 |
Why?
|
| Medicare | 1 | 2010 | 206 | 0.340 |
Why?
|
| Risk Adjustment | 2 | 1999 | 34 | 0.340 |
Why?
|
| Health Services Needs and Demand | 3 | 2019 | 112 | 0.330 |
Why?
|
| Communication | 4 | 2017 | 205 | 0.330 |
Why?
|
| Health Services Research | 7 | 2019 | 271 | 0.320 |
Why?
|
| Aged, 80 and over | 13 | 2017 | 1956 | 0.310 |
Why?
|
| Self Efficacy | 5 | 2017 | 75 | 0.310 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 289 | 0.310 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 316 | 0.300 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2021 | 94 | 0.300 |
Why?
|
| Mass Screening | 4 | 2015 | 678 | 0.300 |
Why?
|
| Employment | 2 | 2018 | 50 | 0.290 |
Why?
|
| Population Surveillance | 3 | 2019 | 270 | 0.290 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 745 | 0.290 |
Why?
|
| Pilot Projects | 4 | 2017 | 235 | 0.290 |
Why?
|
| Fractures, Bone | 3 | 2017 | 91 | 0.290 |
Why?
|
| Risk Factors | 10 | 2020 | 3394 | 0.280 |
Why?
|
| Renal Dialysis | 1 | 2006 | 57 | 0.270 |
Why?
|
| Myocardial Infarction | 3 | 2008 | 251 | 0.270 |
Why?
|
| Prescription Fees | 1 | 2005 | 5 | 0.270 |
Why?
|
| Self Administration | 1 | 2005 | 12 | 0.270 |
Why?
|
| Hyperkalemia | 4 | 2010 | 21 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2023 | 1294 | 0.260 |
Why?
|
| Data Collection | 4 | 2020 | 276 | 0.260 |
Why?
|
| Patient Preference | 2 | 2016 | 49 | 0.260 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 394 | 0.260 |
Why?
|
| Potassium | 4 | 2010 | 20 | 0.260 |
Why?
|
| Health Status Disparities | 2 | 2017 | 154 | 0.260 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 148 | 0.250 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2004 | 8 | 0.250 |
Why?
|
| Logistic Models | 6 | 2019 | 953 | 0.240 |
Why?
|
| Child, Preschool | 9 | 2018 | 1428 | 0.240 |
Why?
|
| Needs Assessment | 3 | 2019 | 73 | 0.240 |
Why?
|
| Truth Disclosure | 2 | 2015 | 19 | 0.230 |
Why?
|
| Heart Diseases | 1 | 2004 | 78 | 0.230 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2020 | 552 | 0.230 |
Why?
|
| Patient-Centered Care | 3 | 2022 | 228 | 0.230 |
Why?
|
| Life Style | 3 | 2017 | 329 | 0.230 |
Why?
|
| Dihydropyridines | 1 | 2003 | 1 | 0.220 |
Why?
|
| Radiation Dosage | 2 | 2013 | 16 | 0.220 |
Why?
|
| Drug Monitoring | 5 | 2010 | 26 | 0.220 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 16 | 0.220 |
Why?
|
| Correspondence as Topic | 3 | 2017 | 8 | 0.220 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2022 | 4 | 0.220 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2022 | 5 | 0.220 |
Why?
|
| Quality of Life | 6 | 2023 | 509 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2014 | 123 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 512 | 0.220 |
Why?
|
| Socioeconomic Factors | 4 | 2013 | 667 | 0.210 |
Why?
|
| Reading | 2 | 2012 | 8 | 0.210 |
Why?
|
| Colorado | 1 | 2023 | 207 | 0.210 |
Why?
|
| Total Quality Management | 2 | 2003 | 30 | 0.210 |
Why?
|
| Diabetes Complications | 1 | 2003 | 120 | 0.210 |
Why?
|
| Information Seeking Behavior | 2 | 2019 | 13 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 8 | 0.200 |
Why?
|
| Medical Records | 3 | 2018 | 108 | 0.200 |
Why?
|
| Attitude of Health Personnel | 3 | 2015 | 227 | 0.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2013 | 105 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 205 | 0.200 |
Why?
|
| Hepatitis C Antibodies | 2 | 2011 | 5 | 0.200 |
Why?
|
| Colonoscopy | 2 | 2015 | 265 | 0.200 |
Why?
|
| Outpatients | 3 | 2008 | 113 | 0.200 |
Why?
|
| Medication Errors | 2 | 2013 | 9 | 0.200 |
Why?
|
| Regression Analysis | 3 | 2014 | 319 | 0.190 |
Why?
|
| Public Health Administration | 1 | 2001 | 7 | 0.190 |
Why?
|
| Safety Management | 1 | 2001 | 16 | 0.190 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 595 | 0.190 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 87 | 0.190 |
Why?
|
| Validation Studies as Topic | 1 | 2020 | 12 | 0.190 |
Why?
|
| Neck Pain | 2 | 2017 | 14 | 0.190 |
Why?
|
| Models, Organizational | 4 | 2004 | 69 | 0.180 |
Why?
|
| District of Columbia | 1 | 2020 | 18 | 0.180 |
Why?
|
| Particulate Matter | 1 | 2020 | 28 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 143 | 0.180 |
Why?
|
| Patient Selection | 2 | 2007 | 194 | 0.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2015 | 643 | 0.180 |
Why?
|
| Interviews as Topic | 6 | 2019 | 327 | 0.180 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2013 | 113 | 0.180 |
Why?
|
| Renin-Angiotensin System | 2 | 2010 | 18 | 0.180 |
Why?
|
| Patient Admission | 1 | 2000 | 72 | 0.180 |
Why?
|
| Foodborne Diseases | 1 | 2019 | 5 | 0.180 |
Why?
|
| Pamphlets | 5 | 2017 | 13 | 0.170 |
Why?
|
| Social Work | 1 | 2019 | 14 | 0.170 |
Why?
|
| Mandatory Reporting | 1 | 2019 | 4 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2000 | 42 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 328 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 98 | 0.170 |
Why?
|
| Psychometrics | 3 | 2017 | 120 | 0.170 |
Why?
|
| Patient Portals | 1 | 2019 | 25 | 0.170 |
Why?
|
| Spironolactone | 2 | 2010 | 9 | 0.160 |
Why?
|
| Self Report | 3 | 2016 | 252 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 1998 | 34 | 0.160 |
Why?
|
| Sex Reassignment Surgery | 1 | 2017 | 3 | 0.160 |
Why?
|
| Economic Recession | 1 | 2018 | 5 | 0.160 |
Why?
|
| Hospital Administration | 1 | 1997 | 4 | 0.160 |
Why?
|
| Risk Management | 1 | 1997 | 6 | 0.160 |
Why?
|
| Pregnancy Complications | 2 | 2012 | 193 | 0.150 |
Why?
|
| Age Factors | 5 | 2016 | 945 | 0.150 |
Why?
|
| Risk Assessment | 7 | 2016 | 1137 | 0.150 |
Why?
|
| Musculoskeletal Diseases | 1 | 2017 | 1 | 0.150 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 12 | 0.150 |
Why?
|
| Workplace | 2 | 2015 | 38 | 0.150 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 30 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 357 | 0.150 |
Why?
|
| Drug Therapy | 3 | 2006 | 24 | 0.140 |
Why?
|
| Creatinine | 2 | 2007 | 67 | 0.140 |
Why?
|
| Disabled Persons | 1 | 2017 | 42 | 0.140 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 13 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 53 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 177 | 0.140 |
Why?
|
| Allostasis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Poverty Areas | 1 | 2016 | 22 | 0.140 |
Why?
|
| Drug Prescriptions | 3 | 2008 | 157 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2016 | 66 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2011 | 692 | 0.140 |
Why?
|
| Heart Failure | 1 | 2021 | 391 | 0.140 |
Why?
|
| Pregnancy | 5 | 2012 | 1484 | 0.130 |
Why?
|
| Family Practice | 1 | 1996 | 58 | 0.130 |
Why?
|
| Likelihood Functions | 3 | 2013 | 49 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 55 | 0.130 |
Why?
|
| Motivation | 1 | 2016 | 133 | 0.130 |
Why?
|
| Risk | 2 | 2014 | 552 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2017 | 198 | 0.130 |
Why?
|
| Educational Measurement | 2 | 2012 | 22 | 0.130 |
Why?
|
| Depressive Disorder | 3 | 2018 | 233 | 0.130 |
Why?
|
| Decision Making | 2 | 2015 | 204 | 0.130 |
Why?
|
| Medical Illustration | 1 | 2014 | 1 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2015 | 60 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 65 | 0.130 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 34 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 486 | 0.130 |
Why?
|
| Vaginal Smears | 1 | 2014 | 46 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2015 | 55 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2014 | 6 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2014 | 11 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2015 | 49 | 0.120 |
Why?
|
| Patient Acuity | 1 | 2014 | 8 | 0.120 |
Why?
|
| Early Detection of Cancer | 3 | 2014 | 510 | 0.120 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 1994 | 8 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 1255 | 0.120 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 49 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 375 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 5 | 0.120 |
Why?
|
| Biometry | 1 | 2013 | 13 | 0.120 |
Why?
|
| Glycated Hemoglobin A | 1 | 2015 | 231 | 0.120 |
Why?
|
| Occupational Health | 1 | 2013 | 20 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2015 | 145 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 125 | 0.110 |
Why?
|
| Community Health Nursing | 1 | 2013 | 2 | 0.110 |
Why?
|
| Home Nursing | 1 | 2013 | 3 | 0.110 |
Why?
|
| Educational Status | 4 | 2017 | 205 | 0.110 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2010 | 12 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 5 | 0.110 |
Why?
|
| Data Mining | 1 | 2013 | 21 | 0.110 |
Why?
|
| Syndrome | 2 | 2023 | 31 | 0.110 |
Why?
|
| Small-Area Analysis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 114 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 705 | 0.110 |
Why?
|
| Health Personnel | 1 | 2014 | 122 | 0.110 |
Why?
|
| Maternal Death | 1 | 2012 | 2 | 0.110 |
Why?
|
| Prevalence | 4 | 2017 | 892 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 56 | 0.110 |
Why?
|
| Incidence | 4 | 2013 | 1297 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 49 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 1309 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 299 | 0.110 |
Why?
|
| Drug Utilization Review | 2 | 2007 | 28 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 57 | 0.110 |
Why?
|
| Family | 1 | 2013 | 119 | 0.110 |
Why?
|
| Cost Control | 2 | 2004 | 27 | 0.110 |
Why?
|
| Social Environment | 2 | 2009 | 93 | 0.100 |
Why?
|
| Sex Factors | 3 | 2011 | 634 | 0.100 |
Why?
|
| Diet | 3 | 2015 | 359 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2012 | 33 | 0.100 |
Why?
|
| Perception | 1 | 2012 | 55 | 0.100 |
Why?
|
| Patients | 1 | 2012 | 39 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 318 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 103 | 0.100 |
Why?
|
| Insurance, Major Medical | 1 | 2011 | 2 | 0.100 |
Why?
|
| Social Class | 1 | 2012 | 125 | 0.100 |
Why?
|
| Patient Care | 1 | 2011 | 37 | 0.100 |
Why?
|
| Eligibility Determination | 1 | 2011 | 18 | 0.100 |
Why?
|
| Drug Costs | 1 | 2011 | 39 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 57 | 0.100 |
Why?
|
| Asthma | 1 | 2014 | 302 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2011 | 28 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2011 | 65 | 0.100 |
Why?
|
| Health Care Reform | 1 | 2011 | 33 | 0.100 |
Why?
|
| Genetic Counseling | 1 | 2011 | 36 | 0.100 |
Why?
|
| Attitude to Computers | 1 | 2011 | 16 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2010 | 19 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2004 | 252 | 0.090 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2011 | 44 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2008 | 11 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2016 | 192 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 1023 | 0.090 |
Why?
|
| Teratogens | 2 | 2008 | 5 | 0.090 |
Why?
|
| Age Distribution | 2 | 2016 | 257 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2013 | 255 | 0.090 |
Why?
|
| Mass Media | 1 | 2010 | 18 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2009 | 118 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2015 | 344 | 0.090 |
Why?
|
| Disease Management | 1 | 2011 | 143 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 118 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2009 | 9 | 0.090 |
Why?
|
| Education | 1 | 2009 | 18 | 0.090 |
Why?
|
| Qualitative Research | 3 | 2019 | 267 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2009 | 48 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 54 | 0.080 |
Why?
|
| Vaccination | 1 | 2014 | 664 | 0.080 |
Why?
|
| Environment Design | 1 | 2009 | 65 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 407 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 197 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 839 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 8 | 0.080 |
Why?
|
| Suicidal Ideation | 2 | 2020 | 102 | 0.080 |
Why?
|
| Lipids | 1 | 2008 | 77 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 19 | 0.080 |
Why?
|
| Pharmacoepidemiology | 2 | 2013 | 22 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2008 | 45 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2007 | 8 | 0.080 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2008 | 28 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 44 | 0.080 |
Why?
|
| Anxiety | 2 | 2020 | 153 | 0.080 |
Why?
|
| Alabama | 2 | 2017 | 23 | 0.080 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2007 | 75 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1164 | 0.070 |
Why?
|
| Anxiety Disorders | 2 | 2018 | 91 | 0.070 |
Why?
|
| Postal Service | 2 | 2022 | 82 | 0.070 |
Why?
|
| Gout | 1 | 2006 | 3 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2016 | 160 | 0.070 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 162 | 0.070 |
Why?
|
| Episode of Care | 1 | 2005 | 14 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 156 | 0.070 |
Why?
|
| Urban Population | 1 | 2006 | 122 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 26 | 0.070 |
Why?
|
| Financing, Personal | 1 | 2005 | 25 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 60 | 0.070 |
Why?
|
| Comorbidity | 2 | 2014 | 618 | 0.060 |
Why?
|
| Health Education | 2 | 2002 | 118 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2006 | 280 | 0.060 |
Why?
|
| Time and Motion Studies | 1 | 2004 | 4 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2004 | 23 | 0.060 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 9 | 0.060 |
Why?
|
| Prognosis | 2 | 2017 | 619 | 0.060 |
Why?
|
| Coitus | 1 | 2003 | 5 | 0.060 |
Why?
|
| Ejaculation | 1 | 2003 | 2 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2003 | 6 | 0.060 |
Why?
|
| Hawaii | 2 | 2015 | 45 | 0.060 |
Why?
|
| Sexual Partners | 1 | 2003 | 37 | 0.060 |
Why?
|
| Massachusetts | 2 | 2015 | 100 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2023 | 35 | 0.060 |
Why?
|
| Respiratory System | 1 | 2022 | 4 | 0.060 |
Why?
|
| Body Weight | 1 | 2004 | 216 | 0.060 |
Why?
|
| Sexual Development | 1 | 2022 | 4 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2003 | 37 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 13 | 0.050 |
Why?
|
| Time Factors | 3 | 2013 | 1114 | 0.050 |
Why?
|
| Cholesterol | 1 | 2003 | 112 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 12 | 0.050 |
Why?
|
| Patient Safety | 2 | 2013 | 43 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 77 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2007 | 852 | 0.050 |
Why?
|
| Office Visits | 1 | 2002 | 85 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 264 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2012 | 1259 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 138 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 188 | 0.050 |
Why?
|
| Continental Population Groups | 2 | 2014 | 317 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 81 | 0.050 |
Why?
|
| Cross Infection | 1 | 2001 | 27 | 0.050 |
Why?
|
| Demography | 1 | 2020 | 106 | 0.050 |
Why?
|
| Organizational Affiliation | 1 | 2000 | 3 | 0.050 |
Why?
|
| Neonatology | 1 | 2000 | 3 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2020 | 69 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2000 | 18 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2012 | 103 | 0.050 |
Why?
|
| Drug Interactions | 1 | 1999 | 21 | 0.040 |
Why?
|
| Poison Control Centers | 1 | 2019 | 3 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2004 | 961 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 160 | 0.040 |
Why?
|
| Exercise | 1 | 2004 | 478 | 0.040 |
Why?
|
| Internet | 2 | 2013 | 247 | 0.040 |
Why?
|
| Length of Stay | 1 | 2000 | 182 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2003 | 504 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 350 | 0.040 |
Why?
|
| Competitive Medical Plans | 2 | 2009 | 3 | 0.040 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 11 | 0.040 |
Why?
|
| Insurance Claim Review | 2 | 2009 | 69 | 0.040 |
Why?
|
| Pediatrics | 1 | 2000 | 164 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 454 | 0.040 |
Why?
|
| Accident Prevention | 1 | 1997 | 4 | 0.040 |
Why?
|
| Systems Analysis | 1 | 1997 | 6 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2009 | 92 | 0.040 |
Why?
|
| Nursing Staff, Hospital | 1 | 1997 | 12 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 1997 | 9 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2018 | 80 | 0.040 |
Why?
|
| Mental Recall | 1 | 2017 | 32 | 0.040 |
Why?
|
| Self-Injurious Behavior | 1 | 2018 | 45 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Temperance | 1 | 2017 | 25 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 29 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 65 | 0.040 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 41 | 0.040 |
Why?
|
| Methods | 1 | 2016 | 8 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2016 | 10 | 0.040 |
Why?
|
| Mental Health | 1 | 2018 | 166 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 1996 | 4 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2016 | 42 | 0.030 |
Why?
|
| Professional Practice | 1 | 1996 | 17 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 266 | 0.030 |
Why?
|
| Physicians, Family | 1 | 1996 | 48 | 0.030 |
Why?
|
| California | 2 | 2018 | 2327 | 0.030 |
Why?
|
| Workload | 1 | 1996 | 31 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2016 | 70 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2017 | 184 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 20 | 0.030 |
Why?
|
| Nutritionists | 1 | 2015 | 2 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 175 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 155 | 0.030 |
Why?
|
| Food | 1 | 2015 | 30 | 0.030 |
Why?
|
| Markov Chains | 2 | 2011 | 26 | 0.030 |
Why?
|
| Peer Group | 1 | 2015 | 50 | 0.030 |
Why?
|
| Energy Intake | 1 | 2015 | 100 | 0.030 |
Why?
|
| Commerce | 1 | 2015 | 49 | 0.030 |
Why?
|
| Africa, Western | 1 | 2014 | 1 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 1 | 0.030 |
Why?
|
| Isoprostanes | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cryptoxanthins | 1 | 2014 | 2 | 0.030 |
Why?
|
| Zeaxanthins | 1 | 2014 | 6 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 3 | 0.030 |
Why?
|
| beta Carotene | 1 | 2014 | 18 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 113 | 0.030 |
Why?
|
| Prenatal Care | 2 | 2007 | 136 | 0.030 |
Why?
|
| Carotenoids | 1 | 2014 | 30 | 0.030 |
Why?
|
| Budgets | 1 | 1994 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 324 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 33 | 0.030 |
Why?
|
| Uncertainty | 1 | 2013 | 8 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 152 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 5 | 0.030 |
Why?
|
| Pharmacovigilance | 1 | 2013 | 1 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 306 | 0.030 |
Why?
|
| Cost of Illness | 1 | 1994 | 97 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 97 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 50 | 0.030 |
Why?
|
| Health Communication | 1 | 2013 | 17 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 249 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 296 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 62 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2012 | 19 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2011 | 2 | 0.030 |
Why?
|
| Contraindications | 1 | 2011 | 16 | 0.030 |
Why?
|
| Ribavirin | 1 | 2011 | 9 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 42 | 0.030 |
Why?
|
| Empathy | 1 | 2011 | 8 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2011 | 84 | 0.020 |
Why?
|
| Awareness | 1 | 2011 | 18 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 158 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1991 | 1 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 96 | 0.020 |
Why?
|
| Health Benefit Plans, Employee | 1 | 1991 | 20 | 0.020 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Public Opinion | 1 | 2010 | 7 | 0.020 |
Why?
|
| Television | 1 | 2010 | 24 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2010 | 92 | 0.020 |
Why?
|
| Parents | 1 | 2013 | 308 | 0.020 |
Why?
|
| Health Care Sector | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 97 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 20 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 33 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1212 | 0.020 |
Why?
|
| Research | 1 | 2008 | 73 | 0.020 |
Why?
|
| Celecoxib | 1 | 2007 | 1 | 0.020 |
Why?
|
| Naproxen | 1 | 2007 | 1 | 0.020 |
Why?
|
| Rhabdomyolysis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Warfarin | 1 | 2008 | 74 | 0.020 |
Why?
|
| Sulfones | 1 | 2007 | 3 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2007 | 4 | 0.020 |
Why?
|
| Lactones | 1 | 2007 | 12 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 10 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 85 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2007 | 15 | 0.020 |
Why?
|
| Informed Consent | 1 | 2007 | 21 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2008 | 165 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2008 | 136 | 0.020 |
Why?
|
| Gout Suppressants | 1 | 2006 | 3 | 0.020 |
Why?
|
| Uric Acid | 1 | 2006 | 12 | 0.020 |
Why?
|
| Diuretics | 1 | 2006 | 18 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 205 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 86 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2005 | 31 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2008 | 346 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 225 | 0.020 |
Why?
|
| Reaction Time | 1 | 2003 | 4 | 0.010 |
Why?
|
| New Jersey | 1 | 2003 | 7 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 9 | 0.010 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2003 | 11 | 0.010 |
Why?
|
| Ohio | 1 | 2002 | 24 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2001 | 20 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 16 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2002 | 236 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 27 | 0.010 |
Why?
|
| Insurance Selection Bias | 1 | 1991 | 7 | 0.010 |
Why?
|
| Oregon | 1 | 1991 | 195 | 0.010 |
Why?
|
| Washington | 1 | 1991 | 384 | 0.010 |
Why?
|